Technology Assessment: Report on the Relative Efficacy of Oral Cancer Therapy for Medicare Beneficiaries Versus Currently Covered Therapy, Part 2. Imatinib for Gastrointestinal Stromal Tumors (GISTs). Table 5

You Are Here: AHRQ Archive Home > Technology Assessment Archive > Report on the Relative Efficacy of Oral Cancer Therapy for Medicare Beneficiaries Versus Currently Covered Therapy

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to www.ahrq.gov for current information.

Table 5. Summary of Efficacy of Imatinib Plus Surgery for GIST

Study ID	Imatinib Dose [length of followup]	No. of Patients, Age,⁶⁶ Sex	GIST Tumor Characteristics	Outcomes Sought	N	%CR	%PR	%SD	%PD
*Phase II*
Bumming, 2003⁵⁵	400 mg/d [mean = 10.7 mo]	17 57 [10-74] 88% M	All patients were high risk or overtly malignant GIST (metastatic disease at presentation) # of prior surgeries 0 = 1 pt 1-3 = 14 pts > 4 = 2 pts non-surgical therapy not stated	Tu response: CT RECIST or PET	Neoadjuvant 1	100% (5pts)	100% (1 pt)
					Adjuvant 5
					Palliative 11		73% (8 pts)	9% (1 pt)	18% (2 pts)
*Retrospective reviews*
Rutkowski, 2003⁵⁶	400-800 mg/d [median followup 7 mos for patients receiving imatinib and 23 mo overall]	35 55 [36-79] 69% M	Patients with C-KIT+ GIST that had liver metastases as documented in the database; all patients underwent surgery 57% complete resection 17% microscopically incomplete resection 26% open biopsy only	Tu response: CT RECIST	Surgery 3
Rutkowski, 2003⁵⁶		35 55 [36-79] 69% M		Tu response: CT RECIST	Imatinib 32		50%	37.5%	12.5%
Scaife, 2003⁵⁷	76% 400 mg imatinib 6% 600 mg Imatinib 18% 800 mg imatinib	17 56 [35-76] 59% M	Unresectable intraabdominal c-KIT+ GISTS by CD117 immunohistochemisty. Patients who received imatinib pre-operatively (neo-adjuvantly) and then underwent surgical exploration for tumor resection.	Tu response: Radiographic change on CT (criteria unclear), PET, or peri-operative pathological specimens; Feasibility of surgical resection after treatment with imatinib.	CT: 17	6%	70%	18%	6%
	76% 400 mg imatinib 6% 600 mg Imatinib 18% 800 mg imatinib	17 56 [35-76] 59% M			PET: 17	55%	27%	2%	0%
	[median followup from imatinib treatment to resection = 10mo; median followup after surgery = 6mos]				Pathology: 17	12%	65%	18%	6%
						94% (complete resection)
Wu, 2003⁵⁸	400-800 mg/d [median followup 18 mo with range 4-81]	57 61 [42-83] 51% M	Diagnosed with GIST and receiving a related surgical resection	OS: Kaplan- Meier Tu response: criteria unclear	All patients who underwent surgery, regardless of use of imatinib.	57	82% complete resections
Wu, 2003⁵⁸	400-800 mg/d [median followup 18 mo with range 4-81]	57 61 [42-83] 51% M		OS: Kaplan- Meier Tu response: criteria unclear	Patients who underwent surgery and were exposed to imatinib in the adjuvant (for high risk disease; N = 3) or palliative (metastatic disease at resection or relapse; N = 26) settings	29	Not clearly stated	85% with initial PR or SD

Return to Document

The information on this page is archived and provided for reference purposes only.